GPRO: Gen-Probe Incorporated Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, July 11, 2012, 5:13 PM Hologic (HOLX) falls slightly AH after: 1) Announcing a $750M debt offering and $3.05B worth of credit facilities to finance its $3.7B acquisition of Gen-Probe (GPRO). 2) Stating the Gen-Probe acquisition is on track to close around August 1. 3) Pre-announcing FQ3 (ended in June) revenue of $470M and EPS of $0.34-$0.35, which compares with a consensus of $477.5M and $0.34. 4) Reaffirming its FY12 guidance. Comment! [Healthcare, Earnings, M&A]
Thursday, June 28, 2012, 11:41 AM Piper Jaffray says the Supreme Court's decision is positive for companies exposed to doctors' offices, with Genomic Health (GHDX -0.8%) likely the biggest beneficiary. Other names that should benefit include: Gen-Probe (GPRO +0.1%), Hologic (HOLX -1.6%), Qiagen (QGEN -1.8%), EXACT Sciences (EXAS -2.8%) and Meriad Genetics (MYGN +0.2%). Comment! [Healthcare, On the Move]
Monday, June 18, 2012, 2:49 PM Jefferies says Hologic's (HOLX +1.2%) pending acquisition of Gen-Probe (GPRO +0.5%) could be a significant earnings driver for the combined company. The firm believes the combination could generate $2.68 in EPS including almost $1.00 in incremental earnings by FY15. Jefferies says HOLX is very attractive at current levels and reiterates a Buy on the name with a $24 price target. Comment! [Healthcare, On the Move]
Monday, May 14, 2012, 12:54 PM Hologic (HOLX +1.6%) ticks higher after JPMorgan ups the shares to Overweight. The firm says the upgrade was made to reflect compelling risk/reward and synergies from the Gen-Probe (GPRO) deal. Its price target is also raised to $22 from $20. Comment! [Healthcare, On the Move]
Monday, April 30, 2012, 10:49 AM Hologic (HOLX) -9.8% following news it's to pay ~$3.7B for Gen-Probe (GPRO), which skies 18.%. While Piper Jaffray's Bill Quirk says that "strategically, this makes all the sense in the world," Dougherty's Junaid Husain is very cautious. Because Gen-Probe is mature, "I am just not sure where they are going to get the accelerated growth." Comment! [M&A, Healthcare, On the Move]
Monday, April 30, 2012, 9:10 AM Premarket gainers: BKS +92%. DMD +38%. SUN +21%. WCRX +20%. GPRO +20%. XOMA +9%. IOC +5%. MNKD +5%. PLX +4%. ARNA +4%. AMRN +3%.
Losers: LDK -14%. SOHU -8%. GNC -5%. HUM -5%. HOLX -4%. SINA -3%. Comment! [On the Move]
Monday, April 30, 2012, 7:55 AM Hologic (HOLX) agrees to acquire Gen-Probe (GPRO) for ~$3.7B in cash, in the pairing of two smidcap healthcare diagnostics companies. GPRO investors will receive $82.75/share, ~20% above its April 27 closing price. GPRO’s molecular diagnostic products include tests for chlamydia and gonorrhea, as well as human papillomavirus. GPRO +19.3%, HOLX +4.8% premarket. Comment! [Healthcare, M&A, On the Move]
Monday, April 30, 2012, 7:13 AM Gen-Probe (GPRO): Q1 EPS of $0.55 beats by $0.04. Revenue of $150M (+7.3% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
Monday, February 13, 2012, 4:17 PM Gen-Probe (GPRO): Q4 EPS of $0.72 beats by $0.04. Revenue of $158.2M (+15.7% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
Monday, February 13, 2012, 12:10 AM Notable earnings after Monday's close: FIS, GPRO, HMA, LPS, MAS, RAX, RGC, SGEN Comment! [Earnings]
Sunday, February 12, 2012, 5:35 PM Notable earnings after Monday's close: FIS, GPRO, HMA, LPS, MAS, RAX, RGC, SGEN 1 Comment [Earnings]
Monday, December 19, 2011, 8:23 AM Deutsche Bank initiates coverage on Gen-Probe (GPRO) with a Buy rating and $70.50 price target. Analysts with the firm see Gen-Probe as a leading player in the +$4.5B MDx market with a promising FY12 pipeline set to help it add product momentum and low double-digit revenue growth Comment! [Healthcare, Quick Ideas]
Monday, October 3, 2011, 3:30 PM It's been a wild ride today for pharmaceutical developer Vermillion (VRML), jumping +19% at the open on positive preliminary results for its PAD drug Vasclir, only to reverse course and tumble -13% as the biotech sector continues to collapse. Other biotech shares getting hit today: Cerus (CERS -5.2%), EXACT Sciences (EXAS -5.2%), Quest Diagnostics (DGX -5.2%), Gen-Probe (GPRO -3.8%), and (CPHD -2.6%). Comment! [Healthcare, On the Move]
Tuesday, September 6, 2011, 2:52 PM Gen-Probe (GPRO +2.4%) gains on a valuation upgrade to speculative buy at Canaccord, citing its new product cycle and strong sector leadership position. Comment! [On the Move]
Tuesday, July 19, 2011, 1:29 PM Gen-Probe (GPRO) -3% on reports that Novartis is no longer pursuing an acquisition. Comment! [Breaking News, On the Move, Healthcare]
Tuesday, July 5, 2011, 10:16 AM TPG's acquisition of Immucor (BLUD +30%) fails to spur comparables Bio-Rad Laboratories (BIO -0.7%) and Gen-Probe (GPRO -1.1%). Takeout multiples were below current diagnostics multiples, Leerink notes, and the P-E buyout likely means there was little interest in BLUD from strategic acquirers. 1 Comment [Healthcare, M&A, On the Move, Quick Ideas]

GPRO Gen-Probe Incorporated

GPRO

Gen-Probe Incorporated